Recent Updates
Recently added Catalysts
WAT Positive Sentiment

Waters Accelerates Oligonucleotide Bioanalysis with the Launch of OligoWorks™ SPE Workflow and Kits News Summary: Delivers up to 2x[i] higher oligonucleotide recovery from biofluids with improved LC-MS sensitivity and reproducibility to support...

Key Takeaway: Waters Corporation has launched OligoWorks SPE Kits aimed at improving bioanalytical quantitation of therapeutic oligonucleotides. These kits promise up to 2x higher oligonucleotide recovery from biofluids and enhance the sensitivity of LC-MS analyses. They are designed to address challenges in sample preparation, potentially accelerating drug development timelines for oligonucleotide therapies. The innovation includes enzyme-enhanced pretreatment for improved mass spectrometer compatibility, allowing for better analytical performance.
Price reaction · baseline $248.51 (2023-10-18 close) · hit after-hours · 2 other WAT headline(s) in the window, move may be shared
day 0 close · peak
+1.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of OligoWorks SPE Kits enhances oligonucleotide recovery and sensitivity.
  • Improvements in reproducibility and lower limits of quantitation are expected.
  • Kits enable automation, improving productivity for scientists.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~19 mo
Low dilution risk
Lead asset
CYTALUX preoperatively
Phase 2 · Esophageal Cancer

Full Press Release Details

MILFORD, Mass. , Oct. 19, 2023 /PRNewswire/ -- Waters Corporation (WAT:NYSE) announces the launch of OligoWorks™ SPE (solid phase extraction) Kits and components to improve sample preparation for LC-MS-based bioanalytical quantitation of therapeutic oligonucleotides. Pharma and biopharma companies developing oligonucleotide therapeutics and the Contract Research Organizations (CROs) that support them can now realize up to a 2x [i] increase over competing products in oligonucleotide recovery from biofluids. The Kits deliver greater reproducibility and LC-MS sensitivity, enabling lower limits of quantitation and reducing the need for repeat experiments.
The pipeline for oligonucleotide therapeutics is rapidly expanding with thirteen FDA approved oligonucleotide therapeutics today, and 500+ in the pipeline. While potent, these highly modified oligonucleotides are challenging to precisely quantify during dosing, metabolism, and tissue distribution studies.
"As a leader in supporting drug development, Waters is committed to solving customer pain points, and enabling greater analytical performance and productivity. Our new OligoWorks SPE Kits directly address oligonucleotide bioanalysis sample prep challenges across diverse oligo therapeutics," said Erin Chambers , Vice President, Consumables and Lab Automation, Waters Corporation. "The science and societal effects of these therapies are exploding given their ability to address human health issues. Our workflow and kits will drive an acceleration of oligo bioanalysis projects and drug development timelines; ultimately improving the experience for drug candidates."
OligoWorks SPE Kits also use an innovative, enzyme-enhanced, and detergent-free sample pretreatment that reduces washing steps and improves mass spectrometer compatibility, thus enabling direct injection LC-MS analysis and lower limits of quantitation. They can also be fully automated for improved productivity, or to simply help scientists gain back time by reducing manual steps and oversight.
Available immediately, OligoWorks SPE Kits and components are another high-performance tool within the growing portfolio of Waters chemistry solutions to support oligonucleotide bioanalysis. They complement Waters best-selling MaxPeak™ Premier Columns, ACQUITY™ Premier LC System and Arc™ Premier LC System, Andrew+™ Pipetting Robot, and the class-leading sensitivity of the Waters Xevo™ TQ Absolute Mass Spectrometer.
Additional Resources
About Waters Corporation ( www.waters.com ) Waters Corporation (NYSE: WAT ), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for over 60 years. With approximately 8,000 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.
Waters, OligoWorks, MaxPeak, ACQUITY, Arc, Andrew+, and Xevo are trademarks of Waters Corporation.

Frequently Asked Questions

What are OligoWorks SPE Kits used for?

OligoWorks SPE Kits enhance sample preparation for LC-MS bioanalysis of oligonucleotides.

How do OligoWorks Kits improve oligonucleotide recovery?

The Kits provide up to a 2x increase in oligonucleotide recovery from biofluids.

What benefits do these kits offer for drug development?

They increase reproducibility and sensitivity, enabling lower quantitation limits.

Are OligoWorks Kits compatible with automation?

Yes, they can be fully automated to enhance productivity and reduce manual steps.

How many oligonucleotide therapeutics are currently FDA approved?

There are currently thirteen FDA approved oligonucleotide therapeutics.

Last updated: Oct 19, 2023